Kornimate/medical-research-clean huggingface dataset:
spermatogonial differentiation via testicular organoid

Conditions: Infertility, Male; Gene Abnormality; Sterility, Male

Summary: purpose: this clinical trial aims to explore the potential for human sperm production in vitro by sustaining a laboratory-cultured adult testicular environment. it also seeks to identify genetic factors contributing to human sterility and failed spermatogenesis. the study's primary objectives include: 1. identifying genomic markers associated with sterility and failed spermatogenesis. 2. developing an ex vivo (outside the body) testis "organ-on-a-chip" ("itestis") to support stem cell cultivation. 3. determining whether human spermatogenesis can be re-created in vitro using stem cells nurtured in the itestis model. study description: researchers will analyze the genomic profiles of fertile and sterile male participants to map genetic abnormalities associated with sterility. using testicular and skin tissue samples from participants, spermatogonial stem cells and pluripotent stem cells will be isolated and utilized to construct the ex vivo itestis. this system will integrate genomic insights and prior research to foster human spermatogenesis outside the body. participant involvement: participants will provide the following samples: * blood sample for serum analysis. * a skin tissue biopsy. * testicular tissue, obtained through fine needle aspiration (fna) or testicular sperm extraction (tese), as part of a routine procedure. all procedures will be conducted by the principal investigator and qualified research staff, ensuring participant safety and adherence to ethical guidelines.


Eligibility criteria:
inclusion criteria: group 1 (fertile control) * male sex of reproductive age (between 18 - 60 years old). * evidence of fertility or normal spermatogenesis. * will undergo study procedures in conjunction with their planned fertility or infertility procedures performed for clinical purposes. inclusion criteria: group 2 and 3 (infertile) * male sex of reproductive age (between 18 - 60 years old). * males with evidence of \>1 year of infertility. * posesses diagnosis of azoospermia is on clinical evaluation. * will undergo study procedures in conjunction with their planned fertility or infertility procedures performed for clinical purposes. exclusion criteria: - the lack of diagnosis of fertility or infertility, and lack of testicles.
trapeziectomy suspensionplasty versus carpometacarpal joint replacement in treatment of basal thumb osteoarthritis

Conditions: Carpometacarpal Osteoarthritis; Rhizarthrosis; Thumb Osteoarthritis

Summary: this study compares and evaluates differences in movement analysis, patient-reported outcome, radiological assesment and muscular function between patients undergoing carpometacarpal joint arthroplasty with use of modern implants and trapeziectomy with suspensionplasty

osteoarthritis of first carpometacarpal joint is the most common degenerative disease of upper limb. according to data available in literature, it affects about 30% of women and 6% of men at the age of 45. increasing with age, it rises up to 90% in people by the age of 80. due to more widely spread electronic devices in offices, at work, at home which requires usage of thumb, increase in numbers mentioned above is strongly probable. the main symptoms are: pain, loose of grip strength and loose of function. the latter is most important fact, since about 50% of hand function is possible only with healthy thumb. in many cases osteoarthritis can be treated by combined nsaids and splinting with rehabilitation. sometimes when symptoms do not respond to non-operative treatment, there is a need for surgery. trapeziectomy is the most common choice for operative treatment for end-stage basal thumb osteoarthritis. however, many other techniques were developed, there is continuous dispute over selecting the optimal . one of the most promising is arthroplasty using prosthesis. last years many important advances were made in a design of implant and materials. moreover the investigators now have many longer outcomes of such operation made in the past. all this data make us think more about using this technique often, since there are papers which show superiority over classical trapeziectomy. even though there are several studies comparing functional and objective outcome of those techniques, there is a lack of evidence in terms of biomechanical analysis, thenar muscle activity and changes in movement patterns. moreover there is no study published so far which considers modern implants and trapeziectomy with suspensionplasty. the aim of the study is to examine relationships between movement analysis (kinematic and functional outcomes), patient reported outcome measures (proms) and x-ray measurement, electromyography both pre- and post-operatively.

Eligibility criteria:
inclusion criteria: * osteoarthritis of carpometacarpal joint iii or iii/iv in eaton classification assessed by two different radiologists * symptoms that do not respond to non-operative treatment for 8 weeks * no counterindications for anaesthesia * signed agreement for taking a part into trial exclusion criteria: * patient do not agree to take a part into study * problems with communication with patient * unstable cardiac disease * reoperations * previous surgical interventions in hand * neuro-muscular diseases * rheumatological background of disease * diagnosed cervical spine disorders

Keywords: thumb osteoarthritis trapeziectomy alloplasty biomechanics
everolimus and octreotide in patients with advanced carcinoid tumor

Conditions: Carcinoid Tumor; Malignant Carcinoid Syndrome

Summary: the purpose of this study was to evaluate whether everolimus 10 mg / day added to treatment with depot octreotide prolongs progression free survival compared to treatment with octreotide alone in patients with advanced carcinoid tumor.


Eligibility criteria:
inclusion criteria: * advanced (unresectable or metastatic) carcinoid tumor * confirmed low-grade or intermediate-grade neuroendocrine carcinoma * documented progression of disease within 12 months prior to randomization. * measurable disease determined by triphasic computer tomography (ct) scan or magnetic resonance imaging (mri). exclusion criteria: * poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoma, or small cell carcinoma. * hepatic artery embolization within the last 6 months or cryoablation of hepatic metastasis within 2 months of enrollment. * previous treatment with mammalian target of rapamycin (mtor) inhibitors (sirolimus, temsirolimus, everolimus) * intolerance or hypersensitivity to octreotide, everolimus, or other rapamycins. * severe or uncontrolled medical conditions * chronic treatment with corticosteroids or other immunosuppressive agent. * other primary cancer within 3 years. other protocol-defined inclusion/exclusion criteria applied

Keywords: cancer carcinoid tumor neuroendocrine carcinoma everolimus octreotide
68ga-pentixafor pet/ct for the subtyping diagnosis of primary aldosteronism

Conditions: Primary Aldosteronism

Summary: to evaluate the value of 68ga-pentixafor pet/ct in the diagnosis of primary aldosteronism subtype

this is a prospective study. we will enroll 100 patients with definite diagnosis of pa using adrenal venous sampling(avs) as the gold standard for subtype to evaluate the value of 68ga-pentixaforpet/ct in the diagnosis of pa.

Eligibility criteria:
inclusion criteria: 1. pa diagnosis confirmed by at least one confirmatory test 2. willingness to undergo avs and surgery 3. informed consent to participate in the study. exclusion criteria: 1. pa patients who met guideline criteria for bypassing avs \[i.e. younger than 35 years old, with typical apa characteristics (plasma aldosterone \>300pg/ml, plasma renin \< 2·5miu/l, serum potassium \<3·5mmol/l, ct indicated unilateral 1cm low-density adenoma); 2. failed adrenal vein cannulation during avs; 3. subtyping diagnosis was inconclusive based on avs results (e.g. aldosterone/cortisol ratio in bilateral adrenal veins lower than the peripheral vein, or missing data); 4. pregnant or lactating women; 5. patients with a history of uncontrolled malignant tumor; 6. concurrent cushing's syndrome \[including mild autonomous cortisol secretion: cortisol after 1mg dexamethasone suppression test (dst)\>138 nmol/l or cortisol after 2mg dst \>50 nmol/l or cortisol after 1mg dst 50-138 nmol/l plus adrenocorticotrophic hormone (acth)\<10pg/ml; 7. diagnosis of familial hyperaldosteronism; 8. imaging characteristics suggestive of pheochromocytoma or adrenal cortical carcinoma; 9. unsuitable for surgery, such as heart failure with new york heart association (nyha) class iii or iv, severe anemia (hemoglobin\<60g/l), stroke or acute coronary syndrome within 3 months, severe ascites and cirrhosis, estimated glomerulus filtration rate\<30ml/min/m; 10. alcohol or drug abuse and mental disorders.

Keywords: pet ct; primary aldosteronism; adrenal venous sampling
a trial of parent-coached exposure therapy for children with anxiety disorders and ocd

Conditions: Anxiety Disorders; Obsessive-Compulsive Disorder

Summary: the purpose of this study is to examine the effectiveness of parent coached exposure therapy (pcet) and standard cognitive behavioral therapy (cbt) in treating childhood anxiety disorders and obsessive compulsive disorder (ocd).

the purpose of this study is to examine the effectiveness of parent coached exposure therapy (pcet) through baseline comparisons, to compare effectiveness of individual pcet and individual standard cognitive behavioral therapy (cbt), to compare efficiency of individual pcet and individual standard cbt, to compare effectiveness of group intensive pcet, individual pcet, and individual standard cbt, and acceptability.

Eligibility criteria:
inclusion criteria: * have a dsm-5 anxiety disorder diagnosis, including generalized anxiety disorder, obsessive compulsive disorder, panic disorder, agoraphobia, separation anxiety disorder, social and specific phobias, as assessed on the relevant modules of the (mini-kids; (sheehan et al., 2010) by study staff in the padc. * be appropriate for the padc standard outpatient therapy program, and be interested in starting outpatient therapy, * have the anxiety disorder as their primary diagnosis, * if taking a selective serotonin reuptake inhibitor, snri, tricyclic, or antipsychotic medication, had no medication changes made at least 8 weeks prior to initiating participation in the study and agree to no changes during the 12 weeks of the study. exclusion criteria: * history of and/or current psychosis, autism, bipolar disorder, or current suicidality, or eating disorder as assessed during the initial clinical interview and all available clinical information. * current positive diagnosis in the child's caregiver of mental retardation, psychosis, or other psychiatric disorders or conditions that would limit his/her ability to understand cbt and follow-through with treatment directives (based on clinical interview). * secondary diagnosis of oppositional defiant disorder or major depression of sufficient severity to prevent anxiety treatment. * severity of symptoms that warrant higher level of care (i.e. intensive, residential, iop, inpatient) * family is unable to attend weekly sessions (i.e. geographical or scheduling barriers) * history of good quality exposure or cbt.
evaluate the safety and feasibility of allogeneic mesenchymal stem cells in patients with multiple sclerosis

Conditions: Multiple Sclerosis; Secondary-Progressive Multiple Sclerosis; Mesenchymal Stem Cells

Summary: to assess the safety and of a single dose of iv infusion of placenta derived mesenchymal stem cells (plmscs) in patients with secondary progressive multiple sclerosis (spms) disease. monitoring will be encompassed baseline assessments and follow-ups over subsequent months, evaluating clinical signs, expanded disability status scale (edss), cytokines, diffusion tensor imaging (dti), functional mri (fmri), cognitive \& psychological evaluations, and flow cytometry for b cell markers.

this open-label phase i study will be conducted in ms clinic of sina and shariati hospital of tehran province . in this study, diagnosis and management of ms patients will be performed based on mcdonald's criteria and iran's diagnostic and treatment protocols. the patients will be received a single injection of plmscs through the intravenous cannula. the proposed study will assess safety and short efficacy endpoints of plmscs administered to 5 patients with spms. the primary objective of the trial is freedom from treatment associated adverse events at 1,3 and 6 months' post treatment. secondary objective will be efficacy as assessed at baseline, at 1,3 and 6 months and will be based on the following: edss, cytokines, dti, fmri, cognitive \& psychological evaluations, and flow cytometry for b cell markers.

Eligibility criteria:
criteria: inclusion criteria: * age between 17-45 years patients with spms . * must be able to sign informed consent . * currently taking rituximab. * disease duration of more than 2 and less than 16 years. exclusion criteria: * pregnancy or breastfeeding. * hepatitis b and c, human immunodeficiency virus (hiv), and human t-cell lymphotropic virus (htlv) disease. * using cytotoxic agents within 3 months prior to the study. * severe anemia (hemoglobin\< 8 mg/dl), coagulation disorders. * history of malignancy . * liver disorders . * significant cardiac, renal or hepatic failure . * active or chronic infection. * life-threatening organ dysfunction. * unable to give written informed consent . * current treatment with an investigational therapy.

Keywords: mesenchymal stem cells multiple sclerosis placenta derived mesenchymal stem cells stem cell therapy neuroimmunology autoimmune disease
incentives in cardiac rehabilitation

Conditions: Cardiovascular Disease

Summary: the objective of this study is to examine whether a financial incentive program increases minutes of moderate-to-vigorous physical activity (mvpa) per week among cardiac rehabilitation (cr) graduates.

a 52-week, randomized, crossover study design will be employed to examine the impact of financial incentives on mvpa among cardiac rehabilitation (cr) program graduates. two experimental therapies, (1) online self-monitoring plus 'virtual rewards' (i.e. badges) (extrack.ca) and (2) online self-monitoring plus 'financial incentives' (extracker.ca), will be administered for six months, one after the other. study participants will be randomly assigned (1:1) to receive these therapies in one of two orders: group a will receive extrack.ca (virtual rewards) for six months, followed by extracker.ca (financial incentives) for the next six months; group b will receive the financial incentive condition first, and the virtual rewards condition second. while exposed to the incentive condition, participants will be eligible to earn financial reward per day exercise is tracked. this study design allows for the assessment of 'real world' uptake of an incentive program among cr patients, since both groups a and b will be able to earn incentives. this design will also help determine if incentives sustain mvpa in the first six months post-cr compared with the virtual rewards condition. finally, the crossover design will allow the exploration of incentive 'timing' - that is, figuring out if incentives more effectively sustain mvpa post-cr if they are offered immediately, versus six months after graduation when patient motivation tends to wane. in addition to tracking exercise sessions using the online self-monitoring tool, participants will be asked to record steps per day, and 10-minute mvpa bouts per day, using a stepscount accelerometer. to check the accuracy of participant entries, participants will be asked to mail-in their accelerometers at the study mid- and end-points (26 and 52 weeks, respectively). participants will also be asked to complete the behavioural regulation to exercise questionnaire (breq-3) at baseline (t1), study mid-point/crossover (t2), and study end-point (t3) as well as cardiopulmonary fitness assessments at t1 and t3.

Eligibility criteria:
inclusion criteria: * cr program graduate (actively participating in program in month six, the final month, of the cr program). exclusion criteria: * no internet access * non-english speaking * diagnosed cognitive disorder * participating in another post-cr intervention study

Keywords: cardiovascular disease cardiac rehabilitation financial incentives outpatient (phase ii) cardiac rehabilitation exercise adherence
a phase i study of ql1604 in subjects with advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: this is a first-in-human (fih), dose-escalation, pk expansion, monotherapy efficacy expansion, and open-label phase i clinical study assessing the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of ql1604 injection （a humanized anti-pd-1 monoclonal antibody）in patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: 1. volunteer to participate in this clinical study; completely understand and know this study as well as sign the informed consent form (icf); 2. age ≥ 18 years and ≤ 70 years when icf is signed; 3. pts with histologically or cytologically confirmed advanced solid tumors; 4. at least one target lesion as defined per recist version (v) 1.1; 5. subjects who have disease progression or intolerable reactions after the currently available standard anti-cancer treatment previously received or refused prior cancer therapy regimen(s) ; 6. eastern cooperative oncology group performance status of 0 or 1; 7. life expectancy of greater than 12 weeks; 8. adequate hematologic and organ function; 9. female subjects who are not pregnant or breastfeeding 10. male and female subjects able to have children must agree to use highly effective method of contraception throughout the study and for at least 120 days after last dose; exclusion criteria: 1. known hypersensitivity to any monoclonal antibody, ql1604 and/or any of its excipients; 2. active autoimmune disease that has required systemic treatment, replacement therapy is acceptable; 3. subjects with major cardiovascular and cerebrovascular diseases; 4. any condition that required systemic treatment with either corticosteroids (\> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before the first dose of study drug; 5. subjects who have received surgery, radiotherapy, chemotherapy, targeted therapy, other anti-tumor treatments, or participating in other clinical studies is less than 4 weeks before the first administration of investigational product; 6. received a live vaccine; 7. infection with human immunodeficiency virus (hiv); 8. known psychiatric or substance abuse disorders that would interfere with the requirements of the study; 9. history or current evidence of any condition, therapy, or laboratory abnormality, that might confound the results of the trial, or interfere with the participant's participation for the full duration of the study, or investigators/sponsor consider the subjects are not suitable for this trial.
relationship between hba1c level, sleep quality and sleep duration

Conditions: Diabetes Mellitus, Type 2; Pre Diabetes; Sleep Disorder

Summary: the study will be conducted during the period of, january 2019 - august 2019 with pre-diabetic participants on a nhs england funded national diabetes prevention program (ndpp) with a clinically diagnosed haemoglobin a1c (hba1c) referral reading of between 42mmol/mol - 47mmol/mol within the last 12 months. the term pre-diabetic can all be used to explain blood glucose levels that are higher than normal, but not high enough for participants to be diagnosed with type 2 diabetes. having high blood glucose levels can increase a participant's risk of developing type 2 diabetes and other health complications, although this is not inevitable. 100 participants will take part in the study. participants will be eligible if they are aged between 18 and 65 years and have an hba1c referral reading of between 42-47mmol/mol within the last 12 months. the participants will be given a written consent form to sign to take part in the study, after receiving both written and verbal information beforehand on the study protocol from the researcher. health screening to determine eligibility for the nhs funded program will be undertaken directly by the intervention provider. study design and procedures: the study will be delivered in a controlled format and will be designed to assess the relationship between the elevation of hba1c level, sleep quality and sleep duration in clinically diagnosed pre-diabetic participants referred and registered to join the nhs ndpp. participants will receive a pre-program information pack in conjunction with a sleep quality and sleep duration questionnaire at the end of their 1:1 initial appointments for the nhs ndpp. participants will be given prepaid envelopes to send their anonymised questionnaires back to the researcher once completed after their appointments. the researcher will ensure confidentiality by keeping all questionnaires in a securely combination coded locked cupboard that only the researcher has access to. participants will be instructed to not write their names on the questionnaires but to only state their gender, age, and referral hba1c reading received from the relevant health care professional.


Eligibility criteria:
inclusion criteria: * participants were eligible if they were aged 18 years - 65 years * had an hba1c referral reading of between 42-47mmol/mol within the last 12 months * registered on the nhse ndpp exclusion criteria: * participants with a severe debilitating disease which may have interfered with the study participation * under the age of 18 years or over the age of 65 years * pregnant

Keywords: hba1c sleep quality sleep duration psqi